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Summary
To reveal the functional significance of hypoxia and angiogenesis in astrocytoma progression, we created genetically
engineered transformed astrocytes from murine primary astrocytes and deleted the hypoxia-responsive transcription factor
HIF-1 or its target gene, the angiogenic factor VEGF. Growth of HIF-1- and VEGF-deficient transformed astrocytes in
the vessel-poor subcutaneous environment results in severe necrosis, reduced growth, and vessel density, whereas when
the same cells are placed in the vascular-rich brain parenchyma, the growth of HIF-1 knockout, but not VEGF knockout
tumors, is reversed: tumors deficient in HIF-1 grow faster, and penetrate the brain more rapidly and extensively. These
results demonstrate that HIF-1 has differential roles in tumor progression, which are greatly dependent on the extant
microenvironment of the tumor.
Introduction 1999a) and increased tumor cell proliferation (Brat et al., 2002;
Holland, 2000). The resultant hypoxia is then thought to induce
Every tissue, including solid tumors, is dependent on adequate new blood vessels that supply the tumor with the necessary
oxygen delivery. Angiogenesis, the formation of new blood ves- metabolites (Brat et al., 2003). In fact, glioblastomas are in part
sels, is a discrete step in tumor progression that is required for defined by the appearance of proliferating endothelial cells and
the expansion of tumor mass (Folkman, 2000). The stage in high blood vessel densities; these distinguish grade IV tumors
which angiogenesis is initiated, however, can vary among tu- from the lower grade astrocytomas histologically (Louis et al.,
mors, depending on the type of malignancy and the microenvi- 2001).
Hypoxic response is triggered to a large extent by the hyp-ronment in which the tumor develops.
Astrocytomas, a class of malignant brain tumors, are very oxia inducible factor-1, or HIF-1, which is composed of a basic
helix-loop-helix transcription factor dimer. This dimer has twooxygen dependent (Brat et al., 2003). Interestingly, low-grade
astrocytomas first acquire their blood supply by coopting exist- components: HIF-1, also known as ARNT, which is constitu-
tively expressed, and HIF-1, which is regulated posttrans-ing normal brain blood vessels, without initiating angiogenesis.
However, when grade III astrocytomas progress to grade IV lationally by ubiquitination-triggered proteolysis (Semenza,
2002b). HIF-1 controls the expression of more than 40 targetastrocytomas/glioblastomas (the most malignant form of astro-
cytoma, also known as glioblastoma multiformae, or GBM), they genes, whose protein products are implicated in angiogenesis,
metabolism, and cell survival (Semenza, 2002a). Although threeshow features of hypoxic and necrotic palisades. These pali-
sades are in part caused by vessel regression (Holash et al., HIF- proteins have been discovered, targeted deletion of the
S I G N I F I C A N C E
The role of hypoxia and angiogenesis in tumor progression has been modeled in numerous studies of malignancy in rodents;
however, less well understood is the role that specific anatomic microenvironments play in determining hypoxic response and
neovascularization in tumorigenesis. We show here that hypoxic response through the HIF-1 transcription factor plays dramatically
different roles, depending on the tissue in which tumors are introduced. HIF-1 is a critical regulator of the production of angiogenic
factors, including the vascular endothelial growth factor (VEGF); this study shows that target-directed therapies, including those that
modulate hypoxic response, may have very different effects, dependent not on the cell type, or malignancy of the tumor, but on
its location and microenvironment.
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HIF-1 gene results in loss of hypoxic responsiveness of virtually extant tissue microenvironment and involves VEGF-dependent
and -independent mechanisms.every HIF-1-regulated transcript (Ryan et al., 2000).
Interestingly, HIF-1 is overexpressed in human glioblas-
Resultstoma biopsies, and the level of expression is correlated with
highest grade of malignancy in human GBM (Zagzag et al.,
Generation of HIF-1-deficient (HIFko) astrocytomas2000). Among the most prominent target genes of HIF-1 is
We isolated astrocytes from the hippocampus of mice homozy-the angiogenic factor VEGF, which is also highly expressed in
gous for a HIF-1/loxP allele (Figure 1A). To assure aggressiveglioblastomas (Chaudhry et al., 2001). These data suggest that
tumor formation, we immortalized and transformed them withHIF-1 and VEGF may be tumor-promoting factors in astrocy-
SV40 large T antigen and the V12-H-ras oncogene, respectivelytoma progression.
(Figure 1A). V12H-ras was chosen because activation of theSeveral laboratories have demonstrated that loss of the HIF-
p21-ras pathway has been implicated in astrocytoma prolifera-1 transcription factor results in reduced growth rates of various
tion and angiogenesis (Feldkamp et al., 1999; Guha et al., 1997),tumors, accompanied in some, but not all, models by decreased
and mouse strains expressing V12-H-ras under the control of avascular density (Maxwell et al., 1997; Ryan et al., 1998, 2000).
glial cell-specific promoter (GFAP) have been shown to developOther studies, however, have pointed in the opposite direction,
high-grade astrocytomas (Ding et al., 2001). Similarly, SV40describing HIF-1 as a tumor suppressor, whose loss gives
large T antigen binds, and thereby inactivates, the two tumorrise to more aggressively growing embryonic stem cell-derived
suppressor proteins p53 and Rb that are commonly lost in
teratocarcinomas (Carmeliet et al., 1998). Thus, the role of the
astrocytoma progression (Louis et al., 2001; Xiao et al., 2002);
hypoxic response, and HIF-1 specifically, during tumor growth in addition, transgenic mice expressing the Rb binding form of
has been controversial. SV40 large T antigen in astrocytes also develop high-grade
One of the confounding variables in these studies has been astrocytomas (Xiao et al., 2002).
the use of a range of cell types (e.g., hepatomas and fibrosar- To obtain HIF-1-null (also known as HIFko) astrocytomas,
comas) and different cell lines within those cell types (e.g., differ- we infected transformed HIF-1 loxP astrocytes with an adeno-
ent embryonic stem [ES] cell lines). This makes comparative virus that expresses the bacteriophage recombinase Cre, or with
studies of the divergent tumors even more difficult to interpret, a control virus expressing -galactosidase. The recombinase
with respect to determining the actual role of hypoxic response efficiently deleted the floxed gene sequences present on the
during tumorigenesis in vivo. two conditional HIF-1 alleles, creating HIF-1-deficient (HIFko)
One of the variables not extensively analyzed thus far in the astrocytomas; real time-PCR analysis did not detect any nonre-
experimental study of HIF-1-deficient tumors is the relation- combinant wild-type cells in adenoviral cre-infected cultures
ship of site of malignancy to tumor progression. Most studies of (data not shown). The adenovirus-treated control astrocytomas
tumor formation have been performed in immunocompromised did not elicit any recombination and were defined as HIF-1
mouse models at subcutaneous sites. Although this is a historic wild-type (also known as HIFwt) astrocytomas (Figure 1A). This
and well-studied site of tumor growth, the subcutaneous space multistep procedure allows a dissection of the role of HIF-1
has a number of intrinsic peculiarities that set it apart from sites in astrocytomas without the complications of using genetically
altered and possibly diverged cell lines, because transformationelsewhere in the mammalian body. These include a lack of
is carried out prior to the removal of the HIF-1 gene by Crespatial constraints in the form of matrix or skeletal elements,
recombinase activity; deletion then occurs at a very low passagerelatively sparse vascularization, and the interface of a number
number.of different tissue types (fat, muscle, connective tissue) found
HIFko astrocytoma cells did not induce transcription of theimmediately under the skin.
HIF-1-regulated genes phosphoglycerate kinase (PGK) andThe role of the tissue vasculature is particularly important
glucose transporter-1 (Glut-1) under hypoxic conditions, whereaswhen considering the hypoxic response of tumors. Tumors vary
HIFwt cells revealed 2- to 6-fold higher RNA levels of thosetremendously from tissue to tissue in degrees of invasiveness,
genes when oxygen levels were decreased (Figure 1B). Slightlylevels of vascular density, and metastatic potential. How much
increased VEGF levels were still observed in HIFko cells becauseof this variation is related to the state of the vasculature in the
VEGF mRNA expression and stabilization is regulated by differ-tissue itself? This is a particularly critical issue when studying
ent mechanisms. Loss of hypoxic response through HIF-1the role of the HIF-1 transcription factor, which is activated by
did not substantially affect cell growth of astrocytomas in vitroalterations in the microenvironment that are controlled by the
(Figure 1C), nor did it change the transformation status of those
local vasculature. It is important to note that many GBM studies
cells as evaluated in a soft agar assay (Figure 1D).
still involve mouse models in which tumors grow subcutane-
ously, in a poorly vascularized environment (Huang et al., 1995; Subcutaneous growth of HIF-1-deficient
Ozawa et al., 1998; Prewett et al., 1999); this contrasts strongly astrocytomas is impaired
with their natural habitat, the highly vascularized brain paren- We next assessed the role of HIF-1 transcriptional response
chyma. in astrocytomas in a standard assay for tumorigenic potential
We investigated whether HIF-1 activity and its downstream in vivo, in which HIFwt and HIFko astrocytoma cell lines were
target, the angiogenic factor VEGF, are driving forces in astrocy- injected subcutaneously into nude mice. Not only did HIFko
toma progression by generating HIF-1- and VEGF-deficient astrocytomas grow more slowly than wild-type astrocytomas,
astrocytomas, and analyzed tumor propagation in two different reaching only 40% of the wild-type tumor weight at 21 days
microenvironments, the subcutaneous and intracranial habitat. postinjection (Figure 2A), but there were also 30% fewer prolifer-
Our study demonstrates that the HIF-1-regulated hypoxic re- ating cells relative to wild-type astrocytomas (Figure 2B). Sur-
prisingly, we did not observe any differences in the number ofsponse to the microenvironment is highly dependent on the
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Figure 1. In vitro characterization of HIF-1 wild-type (HIFwt) and HIF-1-deficient (HIFko) transformed astrocytes
A: Primary hippocampal astrocytes were isolated from HIF-1 loxP mice, immortalized, and transformed with SV40Tag and H-ras. HIF-1-deficient transformed
astrocytes were obtained with the bacteriophage recombinase Cre by deleting the floxed gene sequences of the HIF-1 alleles.
B: HIFwt and HIFko astrocytoma cells were cultured for 8 hr under hypoxic (0.5% pO2) and normoxic (20% pO2) conditions, harvested, and transcription
levels of the hypoxia target genes Pgk, Glut-1, and Vegf A (all isoforms) determined by real-time PCR analysis. Induction of gene transcription was observed in
HIFwt but not in HIFko astrocytes, under hypoxic conditions. Normoxia revealed similar expression levels of these genes in both cell lines. Error bars indicate SEM.
C: Growth rate of HIFwt and HIFko transformed astrocytes under normoxic (20% pO2) and hypoxic (0.5% pO2) conditions. The growth rates of HIF wt and
HIFko cells did not differ under low and high oxygen conditions.
D: HIFwt and HIFko transformed astrocytes formed similar numbers and sizes of colonies in a soft agar colony formation assay. Error bars indicate standard
deviation (SD).
apoptotic cells (Figure 2C). However, more than 70% of the HIF-1-deficient astrocytomas show increased cell
proliferation in the brain but not in thesmall HIFko tumor nodules had hypoxic and necrotic areas,
in contrast to wild-type control astrocytomas, which exhibited subcutaneous habitat
We then injected HIFwt and HIFko astrocytomas intracraniallymuch smaller areas of hypoxic and necrotic palisades (Figures
2E and 2F). The morphology of the tumor cells in the two geno- into the brain parenchyma of nude mice, and compared the
tumor phenotypes observed to the features of astrocytomastypes was indistinguishable (Figures 3A and 3B), and both wild-
type and HIFko astrocytomas grew as encapsulated nodules grown subcutaneously. Both HIFwt and HIFko astrocytomas
showed typical features of high-grade gliomas: in particular,(Figures 3C and 3D).
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infiltrative behavior of the intracerebrally placed tumors in fact
nicely mimics the phenotypes observed in human astrocytomas.
The tumor cells grew along existing blood vessels in the perivas-
cular (Virchow-Robin) spaces in the brain (Figures 6C and 6D)
and tracked along leptomeninges. To our surprise, however,
HIFko astrocytomas invaded even into the collateral hemi-
sphere, being detectable at different locations in both hemi-
spheres of the brain (Figure 6B), as visualized by SV40 large T
antigen staining (which specifically detects the injected tumor
cells).
Although HIFwt astrocytomas were also diffusely growing
(Figure 6C), they stayed focally localized—even at large sizes
as illustrated in Figure 6A—whereas HIFko tumors did not. We
were able to observe small clusters or even single HIF-1-Figure 2. Growth comparison of HIFwt and HIFko astrocytoma in the subcu-
taneous space deficient tumor cells percolating throughout the brain paren-
chyma (Figure 6D), a feature of the diffusely growing tumorA: Mice were inoculated subcutaneously with HIFwt and HIFko astrocytes,
and tumors dissected after 21 days and weighed. HIFko astrocytomas had gliomatosis cerebrii. Covisualization of tumor cells and blood
a reduced tumor weight of 60% compared to HIFwt tumors. vessels revealed that HIFko astrocytomas had become ex-
B: Proliferation index of HIFwt and HIFko tumors was assessed immunohisto-
tremely invasive, tracking along blood vessels in the perivascularchemically by counting Ki-67 positive cells on tumor tissue sections. HIFko
space and moving along leptomeninges in both hemispheresastrocytomas showed a 30% reduction in proliferation rate (p  0.0001).
C: Apoptotic index of HIFwt and HIFko astrocytomas was quantified by (Figure 6D). In summary, loss of HIF-1 in tumors implanted
TUNEL staining on tumor sections. There was no statistical difference in apo- in the brain had an almost diametrically opposed phenotype
ptotic cells between HIFwt and HIFko tumors (p 0.2345). Error bars indicate compared to the phenotype resulting from subcutaneous im-
standard deviation (SD).
plantation. HIFko tumors had become more proliferative, and
invasive, without showing features of large necrotic centers
once implanted intracranially.
they were fast growing, and elicited hypoxic and necrotic pali-
The microenvironment radically alters vascular structuresades. However, striking differences were observed. Mice bear-
and density in experimental astrocytomas,ing HIFwt or HIFko astrocytomas had similar survival times, of
in a HIF-1-dependent fashionapproximately 16–18 days (Figure 4C). This finding indicated
Based on the results above, we suspected that loss of HIF-1that HIF-1-deficient astrocytomas were not smaller than wild-
might affect tumor vascularization differentially in these twotype control tumors in the intracranial habitat which was con-
tumor sites. We sought therefore to visualize and analyze thefirmed by MRI (data not shown) and histopathological analyses
vascular phenotype of both subcutaneous and intracranial(Figures 5A and 5B).
astrocytoma-derived tumors by perfusing the circulatory systemIn contrast to subcutaneously grown astrocytomas, where
with a fluorescent lectin (Figure 7). We found that subcutaneousthe number of dividing cells declined by 30% in the absence
HIFko astrocytomas were rather poorly vascularized, with smallof HIF-1 (Figure 2B), the number of proliferating cells in intra-
patches of distorted blood vessels that surrounded hypoxiccranial HIFko astrocytomas was 30% higher than that in wild-
and necrotic areas (Figure 7D), and vessel densities of onlytype tumors (Figure 4A). No differences in the apoptotic index
52 vessels/mm2 (Figure 7E). Wild-type astrocytomas containedwere observed between wild-type and HIFko astrocytomas (Fig-
50% more blood vessels per unit area than subcutaneous HIFkoure 4B).
tumors (105 vessels/mm2; Figure 7E), a differential likely respon-Interestingly, HIFwt astrocytomas could often be distin-
sible in part for the relatively robust growth of the wild-typeguished morphologically from HIFko astrocytomas. Astrocyto-
tumor cells at this site (Figures 7C and 7E).mas deficient in HIF-1 appeared more spindle-like than wild-
Surprisingly, HIFko astrocytomas in the brain were not onlytype astrocytomas, which also contained mixed cell types (e.g.,
highly vascularized (Figure 7B), but they also exhibited aboutgiant cells (Figures 5A and 5B). Most surprisingly, HIFko astrocy-
50% more blood vessels than the wild-type control astrocyto-tomas did not reveal large necrotic and hemorrhagic centers
mas (Figure 7E); this is the exact opposite of the finding in(Figures 5A–5D) but contained only small areas of hypoxic pali-
subcutaneous growth. The vessel density of HIFko tumors, how-sades, in contrast to the much larger areas seen in wild-type
ever, was still lower than the vessel density of normal brain, acontrol astrocytomas (Figures 5C and 5D). It is important to
highly vascularized organ (380 vessels/mm2 in normal brain ver-note, however, that HIF-1-deficient and wild-type astrocyto-
sus 269 vessels/mm2 in HIFko astrocytomas) (Figure 7E). It ismas were both defined as grade IV or mixed grade III/IV astrocy-
important to note in this context that most tumors, includingtomas by our pathologist.
astrocytomas, exhibit a lower vessel density than the corre-
sponding normal tissue because their oxygen consumption isLoss of HIF-1 increases the invasive capacity
lower than that of normal tissue (Eberhard et al., 2000; Hlatkyof astrocytomas in the brain but not in the
et al., 2002). The majority of HIFko astrocytoma vessels resem-subcutaneous habitat
bled the morphology of the vascular network in normal brainOne important feature of both genotypes of astrocytomas was
(Figure 7B and 7F), appearing slim and organized. This is intheir diffuse growth into the brain parenchyma (Figures 5E–5H)
contrast to blood vessels of HIFwt astrocytomas, which exhib-that contrasted with the encapsulated phenotype of the same
tumor lines grown subcutaneously (Figures 3C and 3D). The ited typical features of a tumor vasculature; i.e., the vessels were
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Figure 3. Illustrative histopathology of subcuta-
neous HIFwt and HIFko astrocytomas
Hematoxylin & eosin (H&E) staining of HIFwt (A)
and HIFko (B) astrocytomas (Bar 40 m). Tumor
cells are morphologically similar. C and D: Hyp-
oxia and necrosis in HIFwt and HIFko astrocy-
tomas. Hypoxic areas (in brown) were visualized
in tumors of pimonidazole-treated mice using
the hypoxyprobe-1 monoclonal antibody (black
arrow); necrotic areas are indicated as “N”
(bar  85 m). HIFko astrocytomas are much
more necrotic than HIFwt astrocytomas. E and
F: Subcutaneous astrocytomas are encap-
sulated as visualized by H&E staining (bar 
200 m).
irregularly shaped, distorted, dilated, and leaky, as indicated by brain vasculature. This would explain the increased degree of
invasion of these fast-growing tumors, likely dictated by theextravasation of fluorescent lectin into the brain parenchyma
(Figure 7A). The most striking differences in vascular morphol- necessity to retrieve sufficient oxygen and nutrients. If this hy-
ogy and density were apparent between HIFko astrocytomas pothesis holds true, then one would expect differing levels of
in the subcutaneous area and brain. Subcutaneous tumors re- angiogenic factors in HIFwt and HIFko astrocytomas. What is
duced to less than 20% in vessel density compared to intracran- the downstream factor of the HIF pathway that determines
ial HIFko tumors, only exposing small patches of distorted blood whether vessels will be coopted or neovascularization will be
vessels (Figures 7E, 7B, and 7D) in contrast to the dense and initiated?
elongated vasculature of HIFko tumors in the brain parenchyma.
HIFwt astrocytomas had similar vessel densities in both set- Loss of VEGF limits tumor growth and regresses
coopted blood vessels in the braintings, but with differences in vessel branching and morphology
of the vasculature between the necrotic areas that covered the VEGF-A (also known as VEGF) is highly expressed in grade
IV astrocytomas/glioblastomas (GBM) and the most prominenttumor (Figures 7A and 7C). The vasculature of subcutaneous
HIFwt astrocytomas appeared less distorted, and showed signs angiogenic candidate, because its transcription is partly induced
by the HIF-1 complex (Ferrara et al., 2003; Pugh and Ratcliffe,of decreased branching, in comparison to the intracranial HIFwt
astrocytomas (Figures 7A and 7C). The surprising result, that 2003). We analyzed VEGF RNA and protein levels in HIFwt
and HIFko cell lines and tumors. VEGF RNA and protein wasthe vasculature of intracranial HIFko tumors resembles normal
brain blood vessels, suggests that these tumors have not under- expressed in both cell lines under normoxic conditions, and
was induced under hypoxic conditions, albeit to a lesser degreegone neovascularization yet, but coopted the existing normal
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Figure 4. Growth comparison of HIFwt and HIFko astrocytoma in the brain
parenchyma
A: Mice were injected intracranially with HIFwt or HIFko astrocytoma and
monitored daily. Mice were sacrificed as soon as they showed side effects
of tumor expansion such as lateral recumbency and weight loss. Survival
Figure 5. Illustrative histopathology of intracranial HIFwt and HIFko astrocy-curves of mice bearing either HIFwt or HIFko astrocytomas are plotted. Mice
tomashad similar survival means (p  0.129)
B: Proliferation index of HIFwt and HIFko tumors was assessed immunohisto- H&E staining reveals hemorrhagic and necrotic areas (white arrow) and
chemically by counting Ki-67 positive cells on tumor tissue sections. HIFko features of giant cells (black arrow) in HIFwt tumors (A), whereas HIFko
astrocytomas showed a 30% relative increase in the proliferation rate (p  tumors (B) often appear more spindle-like with little necrosis (bar  45 m).
0.0001). C and D: Detection of hypoxia and necrosis in HIFwt and HIFko astrocytomas.
C: Apoptotic index of HIFwt and HIFko astrocytomas was quantified by Hypoxic areas (in brown) were visualized in tumors of pimonidazole-treated
TUNEL staining in tumor sections. There was no significant statistical differ- mice using the hypoxyprobe-1 monoclonal antibody (black arrow); ne-
ence in apoptotic cells between HIFwt and HIFko tumors (p  0.1074). Error crotic areas are indicated as “N.” HIFko astrocytomas exhibit only small
bars indicate standard deviation (SD). areas of hypoxia in contrast to HIFwt astrocytomas. H&E staining reveals a
diffuse growth pattern of HIFwt (E) and HIFko astrocytomas (F) (bar  95
m) into the brain parenchyma that is confirmed by SV40 large T antigen
staining (G and H) that detects injected tumor cells (bar  95 m).
in HIFko cells (Figures 1B and 7G). VEGF positive cells were
also detected in intracranially and subcutaneously growing
HIFwt and HIFko astrocytomas as revealed by immunohisto-
served in HIFwt and HIFko astrocytomas are dependent onchemical analysis (Supplemental Figures S1 and S2). Although
downstream activity of VEGF, we generated transformedthe VEGF expression pattern was very heterogeneous at differ-
astrocyte cell lines that were deficient in VEGF. Would tumorsent areas within the tumors, intracranial HIFko tumors appeared
deficient in VEGF behave like those that are deficient in HIF-to have overall lower levels of VEGF protein than the wild-type
1? We employed an approach similar to that described forcontrols, whereas subcutaneous HIFwt and HIFko tumors both
the generation of HIFko astrocytomas (Figure 1A) by isolatingexhibited VEGF levels predominantly around perinecrotic pali-
astrocytes from VEGFloxP mice, wherein exon 3 of the VEGFsades (Supplemental Figure S2).
In order to determine whether the differing phenotypes ob- gene is flanked by loxP recombination sites (Gerber et al., 1999).
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Figure 6. Comparison of invasive behavior in intracranial HIFwt and HIFko astrocytomas
A and B: Invading tumor cells in the brain were detected by SV40 large T antigen staining (in brown). HIFko astrocytomas infiltrate both hemispheres of
the brain (B; bar 1.6 mm), whereas HIFwt astrocytomas, even at large sizes, (A, Bar  1.3 mm) stay focally localized and expand at the site of implantation.
C and D: Tumor-bearing mice were injected i.v. with FITC-labeled tomato lectin (lycopersicon esculentum) to stain blood vessels in green, and then heart-
perfused with 4% paraformaldehyde (PFA), followed by immunohistochemical staining with Cy3-labeled SV40 large T antigen antibody to label tumor cells
in red. Tumor cells are in close contact with normal brain blood vessels, and grow and migrate in the perivascular space. HIFko cells are detected in wide
areas of the normal brain parenchyma (C), whereas HIFwt tumor cells are only detected around blood vessels close to the tumor mass (D).
We then immortalized and transformed VEGFloxP astrocytes (Figures 8B and 8C). VEGFko tumors in the subcutaneous habi-
tat and brain elicited a significantly lower proliferation rate (Fig-with SV40Tag and V12H-ras oncogenes, and in situ excised the
floxed exon 3 of the VEGF gene with an adenovirus expressing ure 8C), and exhibited a higher apoptotic rate than wild-type
tumors (Figure 8D).recombinase Cre (VEGFko astrocytomas). Infection with a con-
trol adenovirus expressing -galactosidase was carried out as Histopathological analysis revealed more necrotic and hyp-
oxic areas in subcutaneously growing VEGFko tumors com-control, resulting in VEGF wild-type astrocytomas (also known
as VEGFwt). pared to VEGFwt tumors (B.B., unpublished data) that can be
partly explained by the 50% lower vascular density in VEGF-Both cell lines were then implanted subcutaneously and
intracranially, tumor growth was observed, and dissected tu- deficient subcutaneous astrocytomas (Figure 8E). These results
are similar to those obtained from subcutaneous HIFko andmors were analyzed for their morphology, proliferation and apo-
ptotic rates, and vascular profile. Similar to HIF-1-deficient HIFwt tumors (Figures 3A–3C and 7E). There were, however,
significant differences between VEGFko and HIFko tumors intumors, VEGFko astrocytomas grew much slower subcutane-
ously than the control VEGFwt tumors, reaching only about 50% the brain parenchyma. VEGFko tumors (Figure 8Fb) did not form
real tumor masses like VEGFwt (Figure 8Fa) or HIFko tumorsof the wild-type tumor weight at 21 days postinjection (Figure
8A). We observed, however, striking differences between HIFko (Figure 5B). Those tumors that were still defined as gradeIII/IV
astrocytomas grew rather in migrating clusters, with necrosisand VEGFko tumors in the brain. VEGFko astrocytomas grew
slower than the control astrocytomas in the brain parenchyma, in some of the centers that were encircled by vascular tumor
nests (Figure 8Fb). Despite this diffusely growing phenotype,and mice had a statistically significant prolonged mean survival
of 30%, compared to mice bearing VEGFwt tumors (p  0.001) VEGF-deficient tumors were not detected in both brain hemi-
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Figure 7. Comparison of vascular morphology and vessel density in HIFwt and HIFko astrocytomas grown in the subcutaneous and intracranial space
To visualize functional blood vessel, tumor-bearing mice were injected i.v. with FITC-labeled tomato lectin (lycopersicon esculentum) and then heart-
perfused with 4% PFA. Brains were frozen in OCT medium and sectioned at 50 m. The vasculature is visualized in green of intracranial (i.c.) HIFwt (A) and
HIFko (B) astrocytomas, and subcutaneous (s.c.) HIFwt (C) and HIFko (D) astrocytomas (bar  130 m). E: Blood vessel density was assessed by counting
vessels/mm2 of 4–5 different tumors per group. Subcutaneous HIFko astrocytomas (D and E) show a 50% reduction in vessel density compared to s.c. HIFwt
tumors (p  0.0317) (C and E), exposing small patches of distorted and leaky vessels. In contrast, intracranial HIFko tumors are highly vascularized (5-fold
higher than s.c. HIFko tumors) and reveal a 50% induction of vessel density in comparison to intracranial HIFwt astrocytomas (p  0.0159) (E). Intracranial
HIFko tumor vessels resemble normal brain blood vessels but show reduced vessel density in comparison to normal brain (B and F) in contrast to the distorted,
dilated, and leaky vessels of intracranial HIFwt tumors in (A). F: Vasculature of normal brain. G: VEGF protein levels were assessed in conditioned medium
of HIFwt and HIFko cells under normoxic and hypoxic (24 hr) conditions by an ELISA assay. VEGF protein levels are elevated in both cell lines under low
oxygen levels.
spheres, but stayed focally localized, in striking contrast to the network of more normal, elongated brain vessels (Figure 7B),
VEGF-deficient tumors revealed a low density of distorted bloodwidespread dissemination of HIFko tumors. The distinct invasive
patterns may be attributed to the differing vascular phenotype vessels; the vasculature was reduced by about 45% relative to
VEGFwt tumors (Figures 8E, 8Fc, and 8Fd). The same relativeof both tumor types. Whereas HIFko tumors contained a dense
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Figure 8. Comparison of cellular and vascular phenotypes of VEGFwt and VEGFko astrocytomas grown in subcutaneous (s.c.) and intracranial (i.c.) space
A: Mice were inoculated s.c. with VEGFwt and VEGFko astrocytomas, and tumors dissected after 21 days and weighed. The tumor weight of VEGFko
astrocytomas was reduced by about 50% in comparison to VEGFwt tumors.
B: When mice were injected i.c. with VEGFwt and VEGFko tumors, mice bearing VEGFko tumors had a 35% longer survival mean than VEGFwt-tumor
bearing mice (p  0.001).
C and D: Proliferative (C) and apoptotic rate (D) of VEGFwt and VEGFko tumors was assessed immunohistochemically by counting Ki-67- or TUNEL-positive
cells, respectively. The proliferation rate was significantly reduced in subcutaneously (p  0.0001) and intracranially (p  0.0001) grown VEGFko tumors.
The apoptotic rate was increased in both s.c. (p  0.0012) and i.c. (p  0.0008) grown VEGFko tumors in comparison to VEGFwt tumors.
E: Blood vessel density was assessed by counting vessels/mm2 of 4–5 fields of different tumors per group. Subcutaneous (p  0.0303) and intracranial (p 
0.0159) VEGFko tumors showed a 40%–50% reduction in vessel density in comparison to the respective wt tumors. Error bars indicate standard deviation.
F: Illustrative histopathology and vascular morphology and density of VEGFwt and VEGFko astrocytomas. a: H&E staining reveals tumor masses of VEGFwt
i.c. tumors with necrotic areas (N). b: VEGFko astrocytomas grow in migrating clusters without forming a real tumor mass. Blood vessels in i.c. (c and d)
and s.c. (e and f) tumors are visualized with a FITC-labeled tomato lectin.
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The hypoxic response is dependentTable 1. Comparison of HIFko and VEGFko astrocytomas in the
subcutaneous and intracranial environment on the vascular microenvironment
What we did not expect was the radical change in tumor behav-HIFko versus HIFwt VEGFko versus VEGFwt
ior when the site of implantation was changed from the com-
s.c. Proliferation ↓ Proliferation ↓
monly exploited subcutaneous site to a site much more reflec-Apoptosis  Apoptosis ↑
tive of the origin of these transformed cells, the intracranialVessel density ↓ Vessel density ↓
Tumor growth ↓ Tumor growth ↓ space. In this microenvironment, HIF-1-deficient tumors be-
Invasion no Invasion no came more motile, moving along the perivascular spaces of
i.c. Proliferation ↑ Proliferation ↓ normal blood vessels, and thereby infiltrating both hemispheresApoptosis  Apoptosis ↑
of the brain. Further, HIF-1-deficient astrocytomas were betterVessel density ↑ Vessel density ↓
Tumor growth ↑ Tumor growth ↓ vascularized than the wild-type tumors, leading to a less necrotic
Invasion ↑↑ Invasion ↑ phenotype in the brain. Nevertheless, the vessel density of HIFko
tumors was lower than that of normal brain. It is important to, no change; ↑, induced; ↓, reduced.
note that it is a hallmark of most tumors that they exhibit a lower
oxygen consumption rate, and therefore a lower vessel density,
than the corresponding normal tissue, allowing tumor cells to
accumulate between capillaries and thereby expanding the in-vascular phenotype was observed in subcutaneously growing
tercapillary distance (Eberhard et al., 2000; Hlatky et al., 2002).VEGFwt and VEGFko tumors; the vasculature of VEGFko tumors
This also holds true for high-grade astrocytomas, because theirwas also reduced by about 50% (Figures 8E, 8Fe, and 8Ff).
microvessel density is lower than that of normal brain tissueIn summary, loss of VEGF in astrocytomas reduced subcuta-
(Eberhard et al., 2000).neous and intracerebral tumor growth by severely impairing
Interestingly, low-grade astrocytomas first coopt existinggrowth and survival of coopted tumor vessels. The tumors re-
brain vessels, and propagate along them; only when these tu-acted differently to the regressing vessels: subcutaneous tu-
mors progress into grade IV astrocytomas/GBM do they be-mors became very necrotic, and showed increased apoptosis,
come neovascularized. It is a peculiar feature of glioblastomaswhereas intracerebral tumors grew along blood vessels in mi-
that they first regress the normal coopted blood vessels withingrating clusters, albeit only in close conjunction to the tumor
the tumor mass before they form new tumor vessels; these(Table 1). Collectively, these results indicate that the hypoxic
are morphologically very distinct from the normal vasculatureresponse of a tumor can determine initiation of new blood ves-
(Holash et al., 1999a, 1999b).sels, or cooption of existing blood vessels, but is highly depen-
Blood vessel regression in astrocytomas is partly causeddent on the local environment in which those tumors arise.
by Angiopoietin-2 (Ang2), a ligand of the receptor tyrosine kinase
Tie-2, which is expressed in endothelial cells (Maisonpierre etDiscussion
al., 1997; Yancopoulos et al., 2000). Ang2 is induced early, whenWe have made the unexpected observation that HIF-1 can act
oxygen levels drop (Abdulmalek et al., 2001), and causes bloodas a negative or positive factor in astrocytoma progression,
vessel regression in the absence of VEGF, but as soon as VEGFdependent on the microenvironment in which tumors grow. Loss
is induced, it will synergize with VEGF in new blood vesselof HIF-1 impairs astrocytoma growth subcutaneously, but in-
formation (Hanahan, 1997). We have obtained preliminary datacreases proliferative and invasive properties of astrocytomas
indicating that Ang2 levels are elevated in intracranial HIFwt, butin the brain. These effects are not observed when VEGF, a
not in HIFko astrocytomas (G.B. and Jocelyn Holash, Regenerondownstream target of HIF-1, is genetically ablated in astrocyto-
Inc., unpublished data). The high levels of Ang2 and the relativelymas (Table 1). VEGF-deficient astrocytomas exhibit a growth
low vessel density further support the notion that the vasculaturedisadvantage in either microenvironment.
of HIFwt tumors undergoes regression and remodeling as indi-How can these opposite effects be explained? Hypoxia is
cated by the appearance of more tortuous and distorted tumora hallmark of grade IV astrocytomas/glioblastomas (GBM), and
blood vessels (Holash et al., 1999a, 1999b; Zagzag et al., 2000).enables these tumors to partly induce angiogenesis in a HIF-
In contrast, HIFko tumors express much lower levels of Ang 21-dependent manner. HIF-1 and its target VEGF are both
and consist of more densely packed elongated blood vessels,highly upregulated in GBMs, and vascular proliferation is a prog-
similar to vessels of normal brain, suggesting that these vesselsnostic marker in GBMs that distinguishes them from lower grade
have not undergone a transition to an angiogenic tumor vascula-astrocytomas. In agreement with predicted behaviors of the
ture.tumors, our subcutaneous astrocytoma studies reveal that loss
Taken together, these observations suggest that HIF-1-of HIF-1, or VEGF, results in poorly vascularized tumors, and
deficient astrocytomas are unable to induce angiogenesis, butcauses severe necrosis and restrained growth in the subcutane-
that they adapt to this disadvantage by behaving like lower-ous space. Thus, loss of HIF-1 or VEGF activity severely im-
grade astrocytomas; i.e., they take advantage of the highly vas-paired astrocytoma growth. These data are in consensus with
cularized environment, and migrate along existing normal bloodresults of other laboratories: that absence of HIF-1 in ES cell-
vessels to propagate. Notably, HIFwt as well as HIFko astrocyto-derived tumors resulted in reduced vascularization within the
mas were histopathologically both defined as grade III/IV ortumor due to a reduced capacity to induce VEGF expression
grade IV astrocytomas.by hypoxia (Carmeliet et al., 1998; Ryan et al., 1998; Tsuzuki
Based on these results, one would expect that VEGFkoet al., 2000). Similarly, genetic ablation of VEGF has been shown
astrocytomas behave similarly to HIFko tumors, and exhibitto cause a dramatic reduction in vascularity and growth of vari-
increased invasive behavior in tumor cells, specifically aroundous tumors (Grunstein et al., 1999; Inoue et al., 2002; Tsuzuki
et al., 2000). normal blood vessels in the brain parenchyma. Surprisingly,
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VEGF-gene ablation in astrocytomas did not induce the pheno- number of studies, although these have been exclusively embry-
onic stem cell-derived teratocarcinomas, injected subcutane-types observed in HIFko astrocytomas when grown intracrani-
ally (summarized in Table 1). Whereas HIFko tumors grew faster ously (Carmeliet et al., 1998). Our study illustrates that the HIF-
1-mediated pathway can positively or negatively influence thethan the wild-type tumors, VEGFko astrocytomas were at a
growth disadvantage. This may be again attributed to their vas- fate and behavior of a tumor, such as an astrocytoma, but
this influence is dependent upon the microenvironment. Thiscular phenotypes: in the brain, HIFko tumors were well vascu-
larized, but VEGFko tumors were poorly vascularized. How can is nicely demonstrated in the cell cycle regulation of HIFko
astrocytomas. Loss of HIF-1 in astrocytomas in the brain re-these discrepancies be explained? Loss of HIF-1 disables hyp-
oxia-dependent VEGF induction, but we found that HIF-1-defi- vealed a higher proliferation index which is similar to the finding
by Goda et al. that p53-deficient fibroblasts and B lymphocytescient tumors still express VEGF, likely due to a combination of
hypoxia-induced stabilization of VEGF mRNA, transcriptional in- can be further pushed into cell cycle when HIF-1 is absent
(Goda et al., 2003). The same transformed HIFko astrocytes,duction by oncogenes such as H-ras, and VEGF expression of
host cells within the tumor. The somewhat lower VEGF levels however, behave the opposite when transplanted into the sub-
cutaneous space; i.e., they grow slower than the control astrocy-maybe sufficient to keep coopted brain vessels functional, but
are not adequate to initiate angiogenesis. Moreover, other addi- tomas, supporting the notion that the microenvironment is an
additional crucial player in cell cycle regulation. Indeed, intra-tional mechanisms, such as downregulation of angiogenic inhib-
itors like thrombospondin-1, might be necessary to induce the cranial HIFko astrocytomas are not very hypoxic and necrotic
and well vascularized, which is an environment that would favorangiogenic switch (Watnick et al., 2003). The situation changes
when VEGF is ablated in tumor cells: although tumors form tumor cell growth. In contrast, HIF-1-deficient astrocytomas
in the subcutaneous space are extremely hypoxic and necroticnests around coopting blood vessels, those start to regress,
which in turn keeps tumor cell proliferation limited. One may and poorly vascularized, a harsh environment that limits tumor
cell growth.argue that the VEGF levels in intracranial VEGFko tumors, made
by host cells, are not sufficient to support the existing vascula-
ture of the growing tumor. The differing phenotypes of HIFko Implications for cancer therapy
Our observation of intracranial HIFko astrocytomas also hasand VEGFko astrocytomas indicate that other factors than VEGF
are likely to be involved in the adaptation of HIF-1-deficient implications for therapy based on HIF-1 targeted inhibition.
tumors to propagate without initiating angiogenesis. Impor- Our data suggest that inhibition of HIF-1, thereby impairing
tantly, the adaptation to become more invasive is also depen- the hypoxic response, might not be a desired strategy to treat
dent on the microenvironment, suggesting an interaction be- astrocytomas, as they might adapt by becoming more invasive
tween tumor cells and host factors in the extracellular matrix and infiltrative.
of the brain parenchyma. Interestingly, gene ablation of VEGF in astrocytomas exhib-
Why do HIFko astrocytomas not coopt blood vessels in the ited a growth disadvantage both in the subcutaneous space
subdermis, and become more invasive as they do in the brain? and the brain, eliciting decreased proliferation rate and vessel
The subcutaneous environment is a very vessel-poor space that density when compared to wild-type astrocytomas, arguing that
requires extensive recruitment and cooptation of vessels for regressing and impairing tumor vessels is a limiting step and
tumor survival. In this context, loss of HIF-1 or VEGF, and a desired therapeutic approach for astrocytomas. This is in
subsequent loss of angiogenic capacity, is likely a negative agreement with the findings that functional ablation of VEGF
factor, resulting in fewer vessels, less proliferation, and slower activity with a neutralizing antibody directed against VEGF re-
growth. This demonstrates that vessel recruitment and angio- sulted in vessel reduction, decreased tumor growth, and in-
genesis are parameters that affect tumor growth in highly vari- creased apoptosis in a rat model of glioblastomas (Rubenstein
able ways. It is quite possible that the differing effects seen due et al., 2000).
to loss of HIF-1 in other laboratories are also tightly linked, In summary, these results emphasize that the microenviron-
not to the cell line involved, but to variations in the space in ment has to be taken into consideration to better understand
which transplanted tumors grow. tumor behavior and adaptation in response to treatment modal-
One could certainly argue that tumors deficient in HIF-1 ities. Indeed, our findings are confirmed by several reports dem-
may adapt other conduits to survive than the ones that we onstrating that the microenvironment and tumor location func-
suggested above. Alternative paths by H-ras or p53-deficiency tionally impacts tumor growth and metastasis. Many tumors
due to ectopic expression of SV40Tag can be likely excluded, have different behaviors when inoculated at sites different from
because astrocytes were first transformed with these onco- their natural environment, most commonly in subcutaneous
genes before HIF-1 was deleted, leading to genetically identi- sites; they become encapsulated, lose their metastatic behavior,
cal cell lines, except for HIF-1 ablation. It is also unlikely that change their morphology, and, indeed, respond differently to
HIF-2 compensates for HIF-1 deficiency in the transformed treatment (Cuenca et al., 1996; MacDonald et al., 2001; Miyoshi
astrocyte cells because we have analyzed HIF-2 protein levels et al., 2000; Taillandier et al., 2003).
in HIFwt and HIFko astrocytoma cell lines, and our preliminary
Experimental proceduresdata suggest that HIF-2 protein is present in our transformed
astrocyte lines, but at low levels, and does not appear to be
Generation of Hif1-WT and Hif1-/, and VEGFwt and VEGF/,induced in the absence of HIF-1 (B.B., unpublished data).
transformed mouse astrocytesTumor-promoting effects of HIF-1 have been demon-
Primary astrocytes were isolated from the hippocampus of 1- to 2-day-old
strated by several groups (Maxwell et al., 1997; Ryan et al., HIF-1f/f (HIFloxP) or VEGFf/f pups. HIF-1f/ mice harbor flanked
1998, 2000; Unruh et al., 2003). The role of HIF-1 as a potential lox P sites of the second exon of the Hif1- allele (Ryan et al., 2000), whereas
VEGFf/f mice contain flanked lox P sites within exon 3 of the VEGF gene“negative factor” in tumorigenesis has been implied by a smaller
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(Gerber et al., 1999). Astrocytes of both mouse strains were isolated as Subcutaneous implantation of HIFwt and HIF/, and VEGFwt
and VEGF/ transformed astrocytesfollows: briefly, after removal of the meninges, the hippocampus was di-
22 athymic mice (4–6 weeks of age; Simonsen laboratory, San Jose, CA)gested with papain (Worthington Biochemical Corporation, Lakewood, NJ)
were implanted subcutaneously with either 100 l of 1  107 HIFwt, or 8at a final concentration of 45 units/ml in a standard enzyme solution con-
athymic mice with 1 107 VEGFwt transformed astrocytes. 21 athymic micetaining 50 mM EDTA, 150 mM CaCl2, 100 mM L-cysteine, and 0.1 g/ml
were injected subcutaneously with 100 l of 1  107 HIFko or 8 mice withDnase in a solution consisting of 1 M HANKS, 10 mM HEPES (Invitrogen,
1  107 VEGFko transformed astrocytes. 21 days postimplantation, tumorsCarlsbad, CA), and 7.5% NaHCO3. The enzyme solution was aspirated and
were harvested, weighed, and processed as described below for immunohis-the digested tissue was washed in astrocyte tissue culture medium: BME
tochemical analyses. All implantation experiments were repeated up to twosupplemented with 10% FBS, 1% penicillin/streptromycin, 1% sodium pyru-
times.vate (all from Invitrogen), 0.6% glucose (Fisher, Los Angeles, CA), and 0.1%
mito-serum extender (Becton Dickinson Biosciences, La Jolla, CA). Single-
Intracranial implantation of HIFwt and HIF/, and VEGFwtcell suspensions were cultured in the medium described and grown at 37	C
and VEGF/ transformed astrocytesin a humidified incubator containing 5% CO2. After one week, primary
35 athymic mice (4–6 weeks of age; Simonsen laboratory, San Jose, CA)astrocytes were purified by shaking the flasks on a rotator at RT at 300 rpm
were implanted intracranially with either 2.5 l of 0.7  106 HIFwt or with(Innova 2000, New Brunswick Scientific, Edison, NJ) and purity confirmed
2.5 l of 0.7  106 HIFko-transformed astrocytes. Similarly, six mice werewith an anti-GFAP antibody. Next, cells were immortalized by stable transfec-
injected with VEGFwt astrocytomas and eight mice with VEGFko-trans-tion with a SV-40 Large T antigen DNA construct. This was carried out by
formed astrocytes. Transplantation site was exactly 2 mm deep into theelectroporation of pMC1neo Poly A (Stratagene, La Jolla, CA) and SV-40
brain parenchyma and 3 mm to the right of the midline behind the breegmaLarge T antigen using a BioRad Gene Pulser 2, set at 975 F, ∞ resistance
using a Hamilton syringe. All the mice were sacrificed between 15 to 21and 250 volts. Starting 48 hr posttransfection, stably transfected cells under-
days postimplantation when they showed side effects of tumor expansionwent G418 selection (300 g/ml; Invitrogen). Resistant colonies were pooled
such as lateral recumbency and weight loss. Mice were anesthetized, heart-and transformed by transfection of a retrovirus containing the H-Ras onco-
perfused with 4% paraformaldehyde (PFA), and then brains either embeddedgene. Thereby, cells were plated in 6-well plates (Corning) at a density of
into paraffin or frozen into OCT medium. All implantation experiments were7 104 cells/well in BME and virus was added to the cells in combination with
repeated up to three times.polybrene (Sigma, St. Louis, MO) at 4g/ml and medium. 48 hr postinfection,
stably transfected cells were selected by Puromycin (Sigma) at a concentra-
Visualization of the vasculaturetion of 1 g/ml. After about 7 to 9 days, clones appeared, and they were
To visualize blood vessels in tumors and normal tissue, mice were firstpooled to obtain a heterogenous group of stably transformed cells, which
anesthetized and injected (i.v.) with 0.05 mg FITC-labeled tomato lectinwere grown in the same medium, containing 5% FBS (Invitrogen). Next,
(lycopersicon esculentum; Vector Laboratories, Burlingame, CA) and thenthe Hif1- exon 2 was deleted by transfecting the cells transiently with an
heart-perfused with 4% paraformaldehyde (PFA). Brains were frozen in OCT,adenovirus expressing either cre recombinase or -galactoside (MOCK). To
sectioned at 50 m, and appropriate sections mounted.determine the efficiency of Hif1- deletion, genomic DNA was isolated from
the cells and the recombination frequency was analyzed by TaqMan Real
Detection of hypoxic areas in tumorsTime PCR analysis.
To allow assessment of the hypoxic regions within tumors, mice were in-
jected i.p. with 60 mg/kg (in w/v PBS) pimonidazole (Hydroxyprobe-1TM,Growth curve and soft agar assay
Natural Pharmacia International Inc.), 1.5 hr prior to sacrifice. Tumors were
For the growth curve, cells were plated in 12-well plates (Corning) in tripli-
resected, processed, and embedded into paraffin. 5 m sections were
cates at a density of 1 105 cells/well in the described tissue culture medium
treated with 0.01% pronase for 40 min. at RT, washed, and incubated with
for transformed astrocytes. Cells were exposed to normoxia 20% pO2 and Hydroxyprobe-1 mouse monoclonal antibody 1(MAb1; Natural Pharmacia
hypoxia 0.5% pO2 for up to 96 hr. Cell counts were performed in duplicate International Inc) at a 1:50 dilution for 40 min at RT. A secondary biotinylated
at each time point using a hemacytometer. For the soft agar assay, cells
goat-anti mouse IgG antibody was applied, and staining visualized using
were plated in triplicates in a 6-well plate at 5  105 cells/well, mixed in
the DAB chromophore (Vector ABC; DAB). Sections were rinsed and counter-
0.35% LMP agarose (Invitrogen, Carlsbad, CA). After culturing the cells for
stained with hematoxylin.
21 days, the wells were stained with 0.005% crystal violet for 4 hr and
analyzed for colony number and size.
Immunohistochemical analysis
HIFwt or HIFko astrocytoma cells in the brain were identified with a rabbit
Real-time PCR assay anti-SV40 Tag antibody. Briefly, slides were deparaffinized and incubated
Cells were grown in 10 cm plates (Falcon) at 7  106 cells/plate and under with the anti-Tag antibody (1:500; gift from Douglas Hanahan at UCSF)
normoxic and hypoxic conditions. After 8 hr incubation, total RNA was followed by treatment with a biotinylated goat anti-rabbit IgG antibody (1:200;
isolated using a Qiagen RNeasy kit according to the manufacturer’s instruc- Vector laboratories, Burlingame, CA). Antibody reactions were revealed with
tions. From 1 g of total RNA, first-strand cDNA was synthesized using an ABC kit, using the chromophore 3,3-diaminobenzidine (DAB) substrate.
SUPERSCRIPT First-Strand (Invitrogen) according to the instructions of the For fluorescent detection, frozen tumor sections were stained with Tag anti-
manufacturer. For real-time PCR detection, 5 ng of input cDNA was analyzed bodies and tumor cells visualized with a CY3-labeled goat anti rabbit IgG
in triplicate per primer pair per sample and the corresponding threshold antibody (1:200; Jackson Immuno Research Laboratories, Inc).
cycle (Ct) values expressed as the mean 
 s.e.m. All reactions were per- In order to visualize tumor cells and the vasculature simultaneously,
formed using 2 Taq Master Mix (Perkin Elmer Applied Biosystems), 900 fluorescent immunohistochemistry was performed with the Tag antibody on
nM of the forward and the reverse PCR primers, and 250 nM of a fluorescently brain cryosections of mice whose vascular system had been perfused FITC-
tagged primer pair-specific probe in a total volume of 25 l using default Lectin prior to euthanasia.
cycling parameters on an ABI Prism 7200 Sequence Detector. The following Apoptotic index was assessed by TUNEL staining (Naik et al., 1996),
primer and probe sequences were used: and proliferating cells were detected with a rat anti-mouse Ki-67 antibody
PGK-1: (F) 5-CAGGACCATTCCAAACAATCTG-3; (R) 5-CTGTGGTAC (1:100; DAKO Corporation, Carpinteria, CA) followed by incubation with a
TGAGAGCAGCAAGA-3; (probe) 5-(6FAM)TAGCTCGACCCACAGCCCTC biotinylated rabbit-anti rat IgG antibody (1:200; Vector laboratories, Burl-
GGCATAT-(TAMRA)-3. ingame, CA) and DAB treatment as described above.
Glut-1: (F) 5-ACGAGGAGCACCGTGAAGAT-3; (R) 5-GGGCATGTGC
TTCCAGTATGT-3; (probe) 5-(6FAM) CAACTGTGCGGCCCCTACGTCTTC- VEGF ELISA
(BHQ)-3. HIFwt and HIFko transformed astrocyte cell lines were cultured under nor-
VEGF total: (F) 5- ATCCGCATGATCTGCATGG-3; (R) 5-AGTCCCATG moxia (20% pO2) and incubated for 24 hr under hypoxic conditions (10%
AAGTGATCAAGTTCA-3; (probe) 5- (6-FAM) TGCCCACGTCAGAGAGCAA pCO2; 0.5% pO2;). Conditioned medium was removed and VEGF levels were
assayed by a sandwich DuoSet ELISA kit (DY493, R&D Systems, San Diego,CATCAC-(BHQ)-3.
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Gerber, H.P., Hillan, K.J., Ryan, A.M., Kowalski, J., Keller, G.A., Rangell, L.,California), according to the manufacturer’s instructions. Each assay condi-
Wright, B.D., Radtke, F., Aguet, M., and Ferrara, N. (1999). VEGF is requiredtion was tested in triplicates.
for growth and survival in neonatal mice. Development 126, 1149–1159.
Statistical analysis Goda, N., Ryan, H.E., Khadivi, B., McNulty, W., Rickert, R.C., and Johnson,
The number of animals was calculated with support from the biostatistician R.S. (2003). Hypoxia-inducible factor 1 is essential for cell cycle arrest
Dr. Alex McMillan at UCSF. Statistical analyses were performed with a two- during hypoxia. Mol. Cell. Biol. 23, 359–369.
tailed, unpaired Mann-Whitney test. Error bars indicate standard deviations
Grunstein, J., Roberts, W.G., Mathieu-Costello, O., Hanahan, D., and John-except for the quantitative RT-PCR analyses, which show SEM. P values
son, R.S. (1999). Tumor-derived expression of vascular endothelial growthless than 0.05 are considered statistically significant.
factor is a critical factor in tumor expansion and vascular function. Cancer
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